We sought to analyse plasma levels of peripheral blood microRNAs (miRs) as biomarkers of ST-segment-elevation myocardial infarction (STEMI) due to type-1 myocardial infarction as a model situation of vulnerable plaque (VP) rupture. Samples of 20 patients with STEMI were compared both with a group of patients without angina pectoris in whom coronary angiogram did not reveal coronary atherosclerotic disease (no coronary atherosclerosis-NCA) and a group of patients with stable angina pectoris and at least one significant coronary artery stenosis (stable coronary artery disease-SCAD). This study design allowed us to identify miRs deregulated in the setting of acute coronary artery occlusion due to VP rupture. Based on an initial large scale miR assay screening, we selected a total of 12 miRs (three study miRs and nine controls) that were tested in the study. Two of the study miRs (miR-331 and miR-151-3p) significantly distinguished STEMI patients from the control groups, while ROC analysis confirmed their suitability as biomarkers. Importantly, this was observed in patients presenting early with STEMI, even before the markers of myocardial necrosis (cardiac troponin I, miR-208 and miR-499) were elevated, which suggests that the origin of miR-331 and miR-151-3p might be in the VP. In conclusion, the study provides two novel biomarkers observed in STEMI, which may be associated with plaque rupture.

Department of Cardiology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Department of Rheumatology Charles University 1st Faculty of Medicine and Rheumatology Institute Prague Czech Republic

Faculty of Science Charles University Prague Czech Republic

Zobrazit více v PubMed

Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur. Heart J. 2016;37:3232–3245. doi: 10.1093/eurheartj/ehw334. PubMed DOI

Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733–43. doi: 10.1161/01.CIR.79.4.733. PubMed DOI

Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am. J. Pathol. 1966;48:19–44. PubMed PMC

Go AS, et al. Heart Disease and Stroke Statistics—2014 Update. Circulation. 2014;129:e28–e292. doi: 10.1161/CIRCULATIONAHA.113.003961. PubMed DOI PMC

Murray CJL, Lopez AD. Measuring the Global Burden of Disease. N. Engl. J. Med. 2013;369:448–457. doi: 10.1056/NEJMra1201534. PubMed DOI

Franco M, Cooper RS, Bilal U, Fuster V. Challenges and Opportunities for Cardiovascular Disease Prevention. Am. J. Med. 2011;124:95–102. doi: 10.1016/j.amjmed.2010.08.015. PubMed DOI

Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. Circ. Res. 2016;118:703–720. doi: 10.1161/CIRCRESAHA.115.306300. PubMed DOI PMC

Economou EK, et al. The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment. Atherosclerosis. 2015;241:624–33. doi: 10.1016/j.atherosclerosis.2015.06.037. PubMed DOI

Kaudewitz, D., Zampetaki, A. & Mayr, M. MicroRNA Biomarkers for Coronary Artery Disease? Genetics, 10.1007/s11883-015-0548-z (2015). PubMed PMC

Kaudewitz D, Zampetaki A, Mayr M. MicroRNA Biomarkers for Coronary Artery Disease? Curr. Atheroscler. Rep. 2015;17:70. doi: 10.1007/s11883-015-0548-z. PubMed DOI PMC

Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating MicroRNAs. Arterioscler. Thromb. Vasc. Biol. 2011;31:2383–2390. doi: 10.1161/ATVBAHA.111.226696. PubMed DOI

Leistner DM, et al. Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics. Eur. Heart J. 2016;37:1738–1749. doi: 10.1093/eurheartj/ehw047. PubMed DOI

Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). Eur. Heart J., 10.1093/eurheartj/ehy462 (2018). PubMed

Zanette DL, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Brazilian J. Med. Biol. Res. = Rev. Bras. Pesqui. medicas e Biol. 2007;40:1435–40. doi: 10.1590/S0100-879X2007001100003. PubMed DOI

Zhao D, Sui Y, Zheng X. miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol. Rep. 2016;35:1075–1082. doi: 10.3892/or.2015.4450. PubMed DOI

Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 2009;284:24696–704. doi: 10.1074/jbc.M109.030098. PubMed DOI PMC

Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. - PubMed - NCBI. Available at, https://www.ncbi.nlm.nih.gov/pubmed/25620533. (Accessed: 14th October 2018). PubMed

Pahl MC, et al. MicroRNA expression signature in human abdominal aortic aneurysms. BMC Med. Genomics. 2012;5:25. doi: 10.1186/1755-8794-5-25. PubMed DOI PMC

Luers AJ, Loudig OD, Berman JW. MicroRNAs are expressed and processed by human primary macrophages. Cell. Immunol. 2010;263:1–8. doi: 10.1016/j.cellimm.2010.03.011. PubMed DOI PMC

Naqvi AR, et al. Expression Profiling of LPS Responsive miRNA in Primary Human Macrophages. J. Microb. Biochem. Technol. 2016;8:136–143. PubMed PMC

Xiao L, Ming H, Tao C, Yuliang W. The expression of SOCS is altered in atherosclerosis. Heart. 2011;97:A51–A51. doi: 10.1136/hrt.2010.214833. DOI

Yang Y, Yang L, Liang X, Zhu G. MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1. Cell. Physiol. Biochem. 2015;36:1371–81. doi: 10.1159/000430303. PubMed DOI

Zhai C, et al. Selective Inhibition of PI3K/Akt/mTOR Signaling Pathway Regulates Autophagy of Macrophage and Vulnerability of Atherosclerotic Plaque. Plos One. 2014;9:e90563. doi: 10.1371/journal.pone.0090563. PubMed DOI PMC

Auge N, et al. Oxidized LDL-Induced Smooth Muscle Cell Proliferation Involves the EGF Receptor/PI-3 Kinase/Akt and the Sphingolipid Signaling Pathways. Arterioscler. Thromb. Vasc. Biol. 2002;22:1990–1995. doi: 10.1161/01.ATV.0000043453.21629.3B. PubMed DOI

Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma|Read by QxMD. Available at, https://www.readbyqxmd.com/read/23458262/concomitant-dysregulation-of-micrornas-mir-151-3p-and-mir-126-correlates-with-improved-survival-in-resected-cholangiocarcinoma, (Accessed: 14th October 2018). PubMed PMC

Yeh T-C, et al. miR-151-3p Targets TWIST1 to Repress Migration of Human Breast Cancer Cells. Plos One. 2016;11:e0168171. doi: 10.1371/journal.pone.0168171. PubMed DOI PMC

Liu X, et al. MicroRNA in vivo precipitation identifies miR-151-3p as a computational unpredictable miRNA to target Stat3 and inhibits innate IL-6 production. Cell. Mol. Immunol. 2018;15:99–110. doi: 10.1038/cmi.2017.82. PubMed DOI PMC

Ni C-W, Qiu H, Jo H. MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. Am. J. Physiol. Circ. Physiol. 2011;300:H1762–H1769. doi: 10.1152/ajpheart.00829.2010. PubMed DOI PMC

Groen HC, et al. High shear stress influences plaque vulnerability Part of the data presented in this paper were published in Stroke 2007;38:2379–81. Neth. Heart J. 2008;16:280–3. doi: 10.1007/BF03086163. PubMed DOI PMC

Cheng C, et al. Atherosclerotic Lesion Size and Vulnerability Are Determined by Patterns of Fluid Shear Stress. Circulation. 2006;113:2744–2753. doi: 10.1161/CIRCULATIONAHA.105.590018. PubMed DOI

Brown AJ, et al. Role of biomechanical forces in the natural history of coronary atherosclerosis. Nat. Rev. Cardiol. 2016;13:210–220. doi: 10.1038/nrcardio.2015.203. PubMed DOI

Rome S. Are extracellular microRNAs involved in type 2 diabetes and related pathologies? Clin. Biochem. 2013;46:937–945. doi: 10.1016/j.clinbiochem.2013.02.018. PubMed DOI

Soeki T, et al. Plasma MicroRNA-100 Is Associated With Coronary Plaque Vulnerability. Circ. J. 2015;79:413–418. doi: 10.1253/circj.CJ-14-0958. PubMed DOI

Cao RY, et al. The Emerging Role of MicroRNA-155 in Cardiovascular Diseases. Biomed Res. Int. 2016;2016:1–5. PubMed PMC

Li C, Chen X, Huang J, Sun Q, Wang L. Clinical impact of circulating miR-26a, miR-191, and miR-208b in plasma of patients with acute myocardial infarction. Eur. J. Med. Res. 2015;20:58. doi: 10.1186/s40001-015-0148-y. PubMed DOI PMC

Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the Vulnerable Plaque. J. Am. Coll. Cardiol. 2006;47:C13–C18. doi: 10.1016/j.jacc.2005.10.065. PubMed DOI

Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of Plaque Formation and Rupture. Circ. Res. 2014;114:1852–1866. doi: 10.1161/CIRCRESAHA.114.302721. PubMed DOI

Willeit P, et al. Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circ. Res. 2013;112:595–600. doi: 10.1161/CIRCRESAHA.111.300539. PubMed DOI

Sunderland N, et al. MicroRNA Biomarkers and Platelet Reactivity. Circ. Res. 2017;120:418–435. doi: 10.1161/CIRCRESAHA.116.309303. PubMed DOI

Laffont B, et al. Activated platelets can deliver mRNA regulatory Ago2bulletmicroRNA complexes to endothelial cells via microparticles. Blood. 2013;122:253–261. doi: 10.1182/blood-2013-03-492801. PubMed DOI

Pordzik J, et al. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Front. Endocrinol. (Lausanne). 2018;9:74. doi: 10.3389/fendo.2018.00074. PubMed DOI PMC

Meder B, et al. Influence of the confounding factors age and sex on microRNA profiles from peripheral blood. Clin. Chem. 2014;60:1200–8. doi: 10.1373/clinchem.2014.224238. PubMed DOI

Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018;39:119–177. doi: 10.1093/eurheartj/ehx393. PubMed DOI

Bao M-H, et al. Meta-Analysis of miR-146a Polymorphisms Association with Coronary Artery Diseases and Ischemic Stroke. Int. J. Mol. Sci. 2015;16:14305–14317. doi: 10.3390/ijms160714305. PubMed DOI PMC

Wang J, Yan Y, Song D, Liu B. Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease. Biomed Res. Int. 2016;2016:4285942. PubMed PMC

Raitoharju, E., Oksala, N. & Lehtimäki, T. MicroRNAs in the Atheroclerotic Plaque, 10.1373/clinchem.2013.204917 (2013). PubMed

Zhu X, et al. Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. Cell. Physiol. Biochem. 2015;36:1359–70. doi: 10.1159/000430302. PubMed DOI

Di Gregoli K, et al. MicroRNA-24 Regulates Macrophage Behavior and Retards Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2014;34:1990–2000. doi: 10.1161/ATVBAHA.114.304088. PubMed DOI

Pilbrow AP, et al. Circulating miR-323-3p and miR-652: Candidate markers for the presence and progression of acute coronary syndromes. Int. J. Cardiol. 2014;176:375–385. doi: 10.1016/j.ijcard.2014.07.068. PubMed DOI

Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Li S, Chen H, Song J, Lee C, Geng Q. Avoiding heparin inhibition in circulating MicroRNAs amplification. Int. J. Cardiol. 2016;207:92–93. doi: 10.1016/j.ijcard.2016.01.129. PubMed DOI

Izraeli S, Pfleiderer C, Lion T. Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood. Nucleic Acids Res. 1991;19:6051. doi: 10.1093/nar/19.21.6051. PubMed DOI PMC

Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques. 2003;35:1140–1144. doi: 10.2144/03356bm03. PubMed DOI

Kaudewitz D, et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb. Haemost. 2013;110:609–615. doi: 10.1160/TH13-05-0368. PubMed DOI